{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:53:24Z","timestamp":1794351204424,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Studies regarding therapeutic response of invasive lobular carcinoma (ILC) to neoadjuvant systemic therapy (NST) suggest that ILC is less favorable and the prognostic impact of a pathologic complete response (pCR) is unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      This study included 853 (NAC;\n                      <jats:italic>n<\/jats:italic>\n                      = 715 and NET;\n                      <jats:italic>n<\/jats:italic>\n                      = 138) non-metastatic classic ILC cases that received NST followed by surgery. Propensity-score matched analysis (PSMA) was performed to compare clinicopathologic groups. Survival outcomes were compared for patients with and without a pCR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Most had large primary tumors with nodal metastases (89.5% cT2\u2013T4, 64% cN+) and luminal subtype tumors (87.6%). Patients receiving NAC were more likely to be clinically node-positive (69.1% versus 34.3%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0005), have grade 3 disease (18.7% versus 8.7%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.0082), and undergo mastectomy (84.2% versus 69.6%;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001) and ALND (84.9% versus 57.3%;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.0001) compared with NET. Overall, breast and axillary nodal pCR rates were 4.9% and 9.3%, respectively. Among 155 patients who had SLNB, there was 1 axillary nodal recurrence (0.6%). The 10-year distant recurrence-free survival (DRFS) for patients with a breast pCR was 61% versus 46% for those without (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.267). Patients with a nodal pCR demonstrated higher 10-year DRFS (49% versus 33%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.026) and OS compared with those without (65% versus 48%;\n                      <jats:italic>p<\/jats:italic>\n                      = 0.068). No survival outcome difference was seen for patients treated with NAC versus NET on PSMA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Nodal pCR was associated with survival outcomes in ILC and systemic therapy decision-making should be reconsidered. SLNB after NST appears to be safe and effective in ILC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20130-4","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T20:48:15Z","timestamp":1783111695000},"page":"9609-9617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical Impact and Outcomes of Neoadjuvant Systemic Therapy for Invasive Lobular Carcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Genevieve A.","family":"Fasano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Mouabbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather Y.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerollos Nashat","family":"Wanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie X.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly K.","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kuerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"3","key":"20130_CR1","doi-asserted-by":"publisher","first-page":"R149","DOI":"10.1186\/bcr767","volume":"6","author":"G Arpino","year":"2004","unstructured":"Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149\u201356.","journal-title":"Breast Cancer Res."},{"issue":"1","key":"20130_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1053\/j.semdp.2009.12.009","volume":"27","author":"EA Rakha","year":"2010","unstructured":"Rakha EA, Ellis IO. Lobular breast carcinoma and its variants. Semin Diagn Pathol. 2010;27(1):49\u201361.","journal-title":"Semin Diagn Pathol."},{"issue":"6","key":"20130_CR3","first-page":"1731","volume":"143","author":"R Moll","year":"1993","unstructured":"Moll R, Mitze M, Frixen UH, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol. 1993;143(6):1731\u201342.","journal-title":"Am J Pathol."},{"issue":"2","key":"20130_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2214\/AJR.07.3827","volume":"192","author":"RF Brem","year":"2009","unstructured":"Brem RF, Ioffe M, Rapelyea JA, et al. Invasive lobular carcinoma: detection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR Am J Roentgenol. 2009;192(2):379\u201383.","journal-title":"AJR Am J Roentgenol."},{"issue":"2","key":"20130_CR5","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1245\/s10434-023-14451-x","volume":"31","author":"AK Schulze","year":"2024","unstructured":"Schulze AK, Hoskin TL, Moldoveanu D, Sturz JL, Boughey JC. Tumor characteristics of bilateral breast cancer compared with unilateral breast cancer. Ann Surg Oncol. 2024;31(2):947\u201356.","journal-title":"Ann Surg Oncol."},{"key":"20130_CR6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejogrb.2024.03.022","volume":"298","author":"G Verboven","year":"2024","unstructured":"Verboven G, Lodewijkx I, Van den Bosch L, et al. Literature review on the bilateral occurrence of invasive lobular breast cancer. Eur J Obstet Gynecol Reprod Biol. 2024;298:74\u20139.","journal-title":"Eur J Obstet Gynecol Reprod Biol."},{"issue":"5","key":"20130_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijsu.2010.04.003","volume":"8","author":"IF Anwar","year":"2010","unstructured":"Anwar IF, Down SK, Rizvi S, et al. Invasive lobular carcinoma of the breast: should this be regarded as a chronic disease? Int J Surg. 2010;8(5):346\u201352.","journal-title":"Int J Surg."},{"issue":"3","key":"20130_CR8","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1002\/cam4.5235","volume":"12","author":"D Akdeniz","year":"2023","unstructured":"Akdeniz D, Kramer I, van Deurzen CHM, et al. Risk of metachronous contralateral breast cancer in patients with primary invasive lobular breast cancer: results from a nationwide cohort. Cancer Med. 2023;12(3):3123\u201333.","journal-title":"Cancer Med."},{"key":"20130_CR9","doi-asserted-by":"crossref","unstructured":"Mathew A, Rajagopal PS, Villgran V et al. A. Distinct pattern of metastases in patients with invasive lobular carcinoma of the breast. Geburtshilfe Frauenheilkd. 2017;77(6):660-666.","DOI":"10.1055\/s-0043-109374"},{"issue":"20","key":"20130_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70061","volume":"131","author":"AN Giaquinto","year":"2025","unstructured":"Giaquinto AN, Freedman RA, Newman LA, Jemal A, Siegel RL. Lobular breast cancer statistics, 2025. Cancer. 2025;131(20):e70061.","journal-title":"Cancer."},{"issue":"2","key":"20130_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s10549-022-06572-w","volume":"193","author":"JA Mouabbi","year":"2022","unstructured":"Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat. 2022;193(2):253\u201364.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"20130_CR12","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-014-2861-6","volume":"144","author":"S Loibl","year":"2014","unstructured":"Loibl S, Volz C, Mau C, et al. Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma. Breast Cancer Res Treat. 2014;144(1):153\u201362.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"20130_CR13","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s10549-011-1735-4","volume":"130","author":"JM Dixon","year":"2011","unstructured":"Dixon JM, Renshaw L, Dixon J, Thomas J. Invasive lobular carcinoma: response to neoadjuvant letrozole therapy. Breast Cancer Res Treat. 2011;130(3):871\u20137.","journal-title":"Breast Cancer Res Treat."},{"key":"20130_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/9781118033050","volume-title":"Statistical Methods for the Analysis of Biomedical Data","author":"RF Woolson","year":"2002","unstructured":"Woolson RF, Clarke WR. Statistical Methods for the Analysis of Biomedical Data. 2nd edn. New York, NY: John Wiley & Sons; 2002.","edition":"2"},{"key":"20130_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/0471722146","volume-title":"Applied logistic regression","author":"DW Hosmer","year":"2000","unstructured":"Hosmer DW, Lemeshow S. Applied logistic regression. 2nd edn. New York, NY: Wiley; 2000.","edition":"2"},{"key":"20130_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric estimator from incomplete observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"20130_CR17","first-page":"163","volume":"50","author":"N Mantel","year":"1966","unstructured":"Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163\u201370.","journal-title":"Cancer Chemother Rep."},{"key":"20130_CR18","doi-asserted-by":"crossref","unstructured":"Cox DR: Regression models and life tables (with discussion). J. R. Statistical Soc, B.1972;34(2):187-202.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"20130_CR19","unstructured":"Parsons LS. \"Reducing bias in a propensity score matched-pair sample using greedy matching techniques\". Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference, Cary, NC: SAS Institute Inc., 2001; http:\/\/www2.sas.com\/proceedings\/sugi26\/p214-26.pdf."},{"issue":"1","key":"20130_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1245\/s10434-015-4603-3","volume":"23","author":"W Truin","year":"2016","unstructured":"Truin W, Vugts G, Roumen RM, et al. Differences in response and surgical management with neoadjuvant chemotherapy in invasive lobular versus ductal breast cancer. Ann Surg Oncol. 2016;23(1):51\u20137.","journal-title":"Ann Surg Oncol."},{"key":"20130_CR21","doi-asserted-by":"crossref","unstructured":"Lips EH, Mukhtar RA, Yau C et al. I-SPY TRIAL Investigators. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012;136(1):35-43.","DOI":"10.1007\/s10549-012-2233-z"},{"issue":"1","key":"20130_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s10549-006-9397-3","volume":"104","author":"C Wenzel","year":"2007","unstructured":"Wenzel C, Bartsch R, Hussian D, et al. Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF. Breast Cancer Res Treat. 2007;104(1):109\u201314.","journal-title":"Breast Cancer Res Treat."},{"issue":"8","key":"20130_CR23","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/annonc\/mdl114","volume":"17","author":"M Tubiana-Hulin","year":"2006","unstructured":"Tubiana-Hulin M, Stevens D, Lasry S, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17(8):1228\u201333.","journal-title":"Ann Oncol."},{"issue":"4","key":"20130_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1053\/ejso.2002.1404","volume":"29","author":"VF Cocquyt","year":"2003","unstructured":"Cocquyt VF, Blondeel PN, Depypere HT, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29(4):361\u20137.","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"20130_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1200\/JCO.2005.03.111","volume":"23","author":"M Cristofanilli","year":"2005","unstructured":"Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol. 2005;23(1):41\u20138.","journal-title":"J Clin Oncol."},{"key":"20130_CR26","first-page":"S106","volume":"88","author":"S Chaturvedi","year":"2004","unstructured":"Chaturvedi S, Heys SD, Chaturvedi RS, et al. Primary chemotherapy for breast cancers: dose histological type of cancer matter? Breast Cancer Res Treat. 2004;88:S106.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"20130_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/01.pas.0000152138.89395.fb","volume":"29","author":"RT Pu","year":"2005","unstructured":"Pu RT, Schott AF, Sturtz DE, Griffith KA, Kleer CG. Pathologic features of breast cancer associated with complete response to neoadjuvant chemotherapy: importance of tumor necrosis. Am J Surg Pathol. 2005;29(3):354\u20138.","journal-title":"Am J Surg Pathol."},{"issue":"2","key":"20130_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/bjc.2012.557","volume":"108","author":"Y Delpech","year":"2013","unstructured":"Delpech Y, Coutant C, Hsu L, et al. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer. 2013;108(2):285\u201391.","journal-title":"Br J Cancer."},{"issue":"2","key":"20130_CR29","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10549-013-2751-3","volume":"142","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Barni S. Response to neoadjuvant chemotherapy in ductal compared to lobular carcinoma of the breast: a meta-analysis of published trials including 1,764 lobular breast cancer. Breast Cancer Res Treat. 2013;142(2):227\u201335.","journal-title":"Breast Cancer Res Treat."},{"issue":"11","key":"20130_CR30","doi-asserted-by":"publisher","first-page":"8243","DOI":"10.1245\/s10434-025-17862-0","volume":"32","author":"RA Mukhtar","year":"2025","unstructured":"Mukhtar RA, Dimitroff K, Yau C, et al. Impact of neoadjuvant chemotherapy on surgical outcomes and conversion to node-negativity in invasive lobular breast cancer: analysis of molecularly high-risk tumors by histologic subtype on the I-SPY2 clinical trial. Ann Surg Oncol. 2025;32(11):8243\u201353.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"20130_CR31","doi-asserted-by":"publisher","first-page":"8353","DOI":"10.1245\/s10434-023-14027-9","volume":"30","author":"P Blumencranz","year":"2023","unstructured":"Blumencranz P, Habibi M, Shivers S, et al. The predictive ttility of MammaPrint and BluePrint in identifying patients with locally advanced breast cancer Who are most likely to have nodal downstaging and a pathologic complete response after neoadjuvant chemotherapy. Ann Surg Oncol. 2023;30(13):8353\u201361.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"20130_CR32","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1245\/s10434-019-07564-9","volume":"26","author":"MJ Thornton","year":"2019","unstructured":"Thornton MJ, Williamson HV, Westbrook KE, et al. Neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in node-positive invasive lobular carcinoma. Ann Surg Oncol. 2019;26(10):3166\u201377.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"20130_CR33","doi-asserted-by":"publisher","first-page":"523","DOI":"10.18053\/jctres.08.202206.009","volume":"8","author":"M G\u00f6ker","year":"2022","unstructured":"G\u00f6ker M, Denys H, van de Vijver K, Braems G. Genomic assays for lobular breast carcinoma. J Clin Transl Res. 2022;8(6):523\u201331.","journal-title":"J Clin Transl Res."},{"issue":"9","key":"20130_CR34","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/cncr.34127","volume":"128","author":"R Weiser","year":"2022","unstructured":"Weiser R, Polychronopoulou E, Hatch SS, et al. Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: a National Cancer Database analysis. Cancer. 2022;128(9):1738\u201347.","journal-title":"Cancer."},{"key":"20130_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.4137\/BMI.S38435","volume":"11","author":"IJ Beumer","year":"2016","unstructured":"Beumer IJ, Persoon M, Witteveen A, et al. Prognostic value of MammaPrint\u00ae in invasive lobular breast cancer. Biomark Insights. 2016;11:139\u201346.","journal-title":"Biomark Insights."},{"issue":"1","key":"20130_CR36","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1245\/s10434-025-18225-5","volume":"33","author":"SR Douglas","year":"2026","unstructured":"Douglas SR, Thomas SM, Chiba A, et al. Contemporary trends in axillary surgery for ER-positive, HER2-negative breast cancer stratified by neoadjuvant endocrine therapy, neoadjuvant chemotherapy, or upfront surgery. Ann Surg Oncol. 2026;33(1):95\u2013107.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"20130_CR37","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/jso.25221","volume":"118","author":"TJ Yu","year":"2018","unstructured":"Yu TJ, Liu YY, Hu X, Di GH. No survival improvement of contralateral prophylactic mastectomy among women with invasive lobular carcinoma. J Surg Oncol. 2018;118(6):928\u201335.","journal-title":"J Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20130-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20130-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:51:09Z","timestamp":1790916669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20130-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20130"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20130-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"10 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no potential conflicts of interest to disclose involving this work.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}